How concerned are you that placing hypogonadal men on testosterone replacement therapy might promote development of prostate cancer (PCa) or progression of undiagnosed PCa?

Share this content:

Many physicians remain wary about starting testosterone replacement therapy (TRT) in hypogonadal men in large part out of concern that it could cause progression of undiagnosed prostate cancer (PCa) or promote PCa development.

Recently, British researchers published findings from a study in which 1,365 men receiving TRT for symptomatic androgen deficiency were followed for up to 20 years (J Sex Med; published online ahead of print).

They found that the incidence of PCa was equivalent to that expected in the general population. They concluded: “Physicians and surgeons considering the many potential benefits of TRT for their patients should not be deterred from giving it by theoretical fears, where careful and regular safety monitoring is in place.”

Renal & Urology News would like to find out how urologists view the use of TRT, so please answer the following poll question.

Leave a comment below to explain your choice.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters